Media Room

Welcome, and thank you for accessing our Media Room, which is your gateway to relevant information about the HIV Vaccine Trials Network (HVTN).  We are a team of people on a scientific journey to find an effective preventive HIV vaccine.  Our work is made possible through the commitment of our heroes – individuals, families, and communities around the world who contribute to the success and impact of our work.

To view a full list of News Releases, please visit our News Releases page.


Recent Press Releases

JULY 9, 2020 – Harmonizing efforts to conduct large scale COVID-19 vaccine efficacy trials 

A clinical trial called CoVPN 5001 will help the newly formed COVID-19 Prevention Network (CoVPN) understand early SARS-CoV-2 infection and the body’s early immune responses to the virus that causes COVID-19 illness. Gathered from diverse populations worldwide, the data obtained through this study will describe viral progression and immunological characteristics of early infection with SARS-CoV-2. Information about the clinical course of SARS-CoV-2 infection, especially during its early stage, is needed to close knowledge gaps and will potentially suggest markers of protection that could be used in evaluating the efficacy of future COVID-19 vaccine candidates.
Read more >

 

JULY 1, 2020 – HVTN participates in 23rd International AIDS Conference (virtual)

Join us in wishing Susan Buchbinder, M.D., Director of Bridge HIV at the San Francisco Department of Public Health and Stephaun E. Wallace, Ph.D., HVTN’s Director External Relations the best on their talks at the conference. Rafael Gonzalez, Community Programs Manager at Bridge HIV, San Francisco Department of Public Health will present a virtual poster presentation.   
Read more >

 

MAY 14, 2020 –  Skilled partners in the conduct of HIV prevention trials join COVID-19 response

The NIH-funded HIV Vaccine Trials Network (HVTN) and HIV Prevention Trials Network (HPTN) have initiated their first clinical trial in response to COVID-19. The study, called HVTN 405/HPTN 1901, is underway at clinical trial sites across North and South America and will describe immune responses in study participants with a history of infection with SARS-CoV-2, the virus that causes COVID-19.
Read more >

 

MAY 11, 2020 – Fred Hutch, NIH experts outline plan for COVID-19 vaccines

In a Science perspective, experts urge multi-pronged, coordinated approach to successfully develop COVID-19 vaccines. Unprecedented collaboration and resources will be required to research and develop safe and effective vaccines for COVID-19 that can be manufactured and delivered in the scale of billions of doses to people globally. Read more >

 

APRIL 1, 2020 – Public statement by the HIV Vaccine Trials Network (HVTN) on Covid-19

The HVTN continues to monitor the impact of COVID-19 on the conduct of the early and large-scale clinical trials we coordinate globally.  We remain committed to the safety and wellbeing of all study participants and study teams. Read more >

 

APRIL 1, 2020 – The HVTN and HPTN Remember Gita Ramjee

Gita Ramjee, PhD, renowned for her extensive work on HIV prevention and a valued colleague to so many in the HIV Vaccine and Prevention Trials Networks (HVTN and HPTN), sadly succumbed to complications associated with SARS-CoV-2 infection.

 

MARCH 23, 2020 – Public statement by the HIV Vaccine Trials Network (HVTN) on Covid-19

The COVID-19 pandemic is evolving rapidly and impacting each country and community differently. The leadership of the HVTN, in consideration of the impact of COVID-19, is committed to ensuring the safety and welfare of all study participants and study teams making the early phase and large-scale clinical trials coordinated by the Network possible. Read more >

 


To view a full list of News Releases, please visit our News Releases page.